- Home
- KGC vs GMAB Comparison
KGC vs GMAB Comparison
Compare KGC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGC
- GMAB
- Stock Information
- Founded
- KGC 1993
- GMAB 1999
- Country
- KGC Canada
- GMAB Denmark
- Employees
- KGC N/A
- GMAB N/A
- Industry
- KGC Precious Metals
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KGC Basic Materials
- GMAB Health Care
- Exchange
- KGC Nasdaq
- GMAB Nasdaq
- Market Cap
- KGC 12.0B
- GMAB 12.1B
- IPO Year
- KGC N/A
- GMAB N/A
- Fundamental
- Price
- KGC $10.97
- GMAB $22.34
- Analyst Decision
- KGC Buy
- GMAB Buy
- Analyst Count
- KGC 3
- GMAB 9
- Target Price
- KGC $11.00
- GMAB $40.71
- AVG Volume (30 Days)
- KGC 23.9M
- GMAB 1.9M
- Earning Date
- KGC 02-12-2025
- GMAB 02-12-2025
- Dividend Yield
- KGC 1.09%
- GMAB N/A
- EPS Growth
- KGC 126.95
- GMAB 83.82
- EPS
- KGC 0.77
- GMAB 16.85
- Revenue
- KGC $5,148,800,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- KGC $9.85
- GMAB $18.78
- Revenue Next Year
- KGC $1.41
- GMAB $14.98
- P/E Ratio
- KGC $14.24
- GMAB $12.94
- Revenue Growth
- KGC 21.44
- GMAB 30.67
- 52 Week Low
- KGC $4.75
- GMAB $18.64
- 52 Week High
- KGC $12.29
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- KGC 46.63
- GMAB 65.39
- Support Level
- KGC $11.14
- GMAB $18.74
- Resistance Level
- KGC $11.74
- GMAB $22.55
- Average True Range (ATR)
- KGC 0.37
- GMAB 0.46
- MACD
- KGC -0.12
- GMAB 0.39
- Stochastic Oscillator
- KGC 1.49
- GMAB 94.64
About KGC Kinross Gold Corporation
Kinross Gold is a Canada-based gold producer, producing roughly 2.2 million gold equivalent ounces in 2023. The company had about a decade of gold reserves at the end of 2023. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. The company has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada, which, if developed, could produce an average of more than 500,000 ounces of gold per year for at least a decade.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.